Cabergoline (Caberlin): What It Treats, How to Dose It, and What to Watch For

What cabergoline is and how it works

Cabergoline is an ergot-derived dopamine agonist with high selectivity for the D2 dopamine receptor. To understand why that matters, you need one piece of physiology.

Prolactin is made by lactotroph cells in the anterior pituitary. Unusually among pituitary hormones, prolactin is under tonic inhibition rather than tonic stimulation. The hypothalamus continuously suppresses it by releasing dopamine, which travels down the pituitary stalk and binds D2 receptors on the lactotrophs. Dopamine is, in effect, the foot permanently on the brake.

Cabergoline binds those same D2 receptors and presses that brake harder. Prolactin secretion drops. That is the entire mechanism, and it explains everything else about the drug, including why it also causes nausea (dopamine receptors in the brainstem chemoreceptor trigger zone) and dizziness on standing (dopamine's effect on vascular tone).

The property that defines cabergoline clinically is its half-life: approximately 65 hours. It also has a very long residence time on the pituitary receptor itself. This is why it is dosed twice weekly rather than daily, and it is the main practical advantage over bromocriptine, which has to be taken every day, sometimes multiple times a day.

What it actually treats

Hyperprolactinaemia and prolactinoma

This is the licensed indication and the reason most people take it. Excess prolactin causes a fairly specific cluster of problems. In women: irregular or absent periods, infertility, and galactorrhoea (inappropriate milk production). In men: reduced libido, erectile dysfunction, infertility, and sometimes gynaecomastia. In both sexes, if the cause is a large pituitary tumour pressing on the optic chiasm, visual field loss.

Cabergoline works on both fronts. It normalises prolactin in the large majority of patients, and in prolactinomas it shrinks the tumour itself, often substantially. This is why medical therapy has largely displaced surgery as first-line treatment for prolactinomas, which is genuinely unusual: it is one of the few solid tumours where a tablet is the standard first move rather than an operation.

Fertility is often restored as prolactin normalises. That is worth knowing in both directions. Women who were not ovulating because of high prolactin can start ovulating again, sometimes before periods become regular, which means pregnancy can occur before it is expected. If you are taking cabergoline and do not want to conceive, use contraception.

Other uses

Cabergoline is used off-label or in specific settings for suppression of lactation, and at much higher doses as an adjunct in Parkinson's disease. The Parkinson's dosing is an order of magnitude above prolactin dosing, and it is where the cardiac valve concerns originate. That distinction matters and is covered below.

It is also used off-label in acromegaly, and there is a body of interest around its use in men for other purposes that is not supported by good evidence. If you are considering cabergoline for anything other than a documented prolactin problem, be honest with yourself about what the evidence actually supports, which is not much.

Dosing: why twice a week, and why slowly

The standard starting dose for hyperprolactinaemia is 0.25mg twice a week. Not 0.5mg. Not daily. This is what Caberlin 0.25mg exists for.

Dose escalation is deliberately slow. The typical approach is to increase by 0.25mg twice weekly at monthly intervals, guided by serum prolactin levels, up to a usual maximum of 1mg twice weekly. Most people do not need to go anywhere near the top of that range. Many are controlled on 0.5mg per week total.

Two reasons for the slow escalation, and both are worth understanding rather than resenting:

• Tolerability. Nausea and dizziness are common at initiation and largely dose-related. Starting low and going slow gives the body time to accommodate. Rushing the titration is the single most common reason people abandon the drug.
• You often do not need more. Because prolactin responds well, escalating on a schedule rather than on measured prolactin levels means overshooting the dose you actually need. Dose should follow the blood test, not the calendar.

Take it with food. This meaningfully reduces the nausea. Taking it in the evening, so you sleep through the peak, is a common and sensible tactic. Getting up slowly from sitting or lying, especially in the first weeks, reduces the dizziness.

Treatment is long term but not necessarily lifelong. In many patients with prolactinoma, after a sustained period of normal prolactin and tumour shrinkage, a supervised withdrawal attempt is reasonable. A meaningful proportion stay in remission. This is a decision for the endocrinologist managing you, not one to make unilaterally.

Side effects and the valve question

Common, especially early: nausea, headache, dizziness, fatigue, constipation, abdominal pain, and postural hypotension. Most improve as the body adapts. Food, evening dosing and slow titration are the three levers that fix most of it.

Impulse control disorders. This is underdiscussed and it is important. Dopamine agonists as a class can cause pathological gambling, compulsive shopping, hypersexuality, and binge eating. These are not moral failings, they are a pharmacological effect on the dopaminergic reward system, and they can appear in people with no prior history. They are far better documented at the high doses used in Parkinson's disease than at prolactin doses, but they have been reported at prolactin doses too. If you or, importantly, the people around you notice new compulsive behaviour, tell the prescriber. People experiencing this frequently do not recognise it themselves.

The cardiac valve question. Here is the honest version. Ergot-derived dopamine agonists including cabergoline and pergolide have an affinity for the 5-HT2B serotonin receptor. Stimulating that receptor on heart valve tissue can drive fibrotic thickening, causing valve regurgitation. Pergolide was withdrawn from the US market over this. Cabergoline carries the same theoretical risk.

The critical qualifier is dose. The valve disease signal is clear and consistent at the high cumulative doses used in Parkinson's disease, which are typically several milligrams per day. Prolactin dosing is a fraction of that, often 0.5mg to 2mg per week in total. Studies at prolactin doses have been broadly reassuring, with most finding no significant increase in clinically important valve disease. That is not the same as zero risk, and product labelling reflects that: echocardiographic assessment before starting and periodic monitoring during long-term treatment is standard guidance. Do not skip that because a forum told you it was overcautious.

Other serious effects to know: pleural and retroperitoneal fibrosis (rare, same fibrotic mechanism), and sudden onset of sleep, which is a documented dopamine agonist effect and has obvious implications for driving.

Interactions and who should not take it

• Dopamine antagonists directly oppose cabergoline. This includes many antipsychotics (haloperidol, risperidone, and others) and the antiemetic metoclopramide. These drugs are also, notably, a very common cause of raised prolactin in the first place. If your high prolactin is drug-induced, the correct fix is usually to address the causative drug, not to layer cabergoline on top of it.
• Strong CYP3A4 inhibitors such as ketoconazole, itraconazole and ritonavir raise cabergoline levels.
• Macrolide antibiotics such as erythromycin increase systemic exposure.
• Antihypertensives. Cabergoline lowers blood pressure. Combining it with other blood pressure lowering drugs compounds the postural hypotension.

Do not take cabergoline if you have: a history of cardiac valvular disorders, a history of pulmonary, pericardial or retroperitoneal fibrotic disorders, uncontrolled hypertension, or a known hypersensitivity to ergot alkaloids. Severe hepatic impairment requires a lower dose.

Before starting long-term treatment, a baseline echocardiogram is standard. This is not a formality and it is not a way of selling you an extra test. It is how the valve risk is actually managed.

Cabergoline vs bromocriptine

Cabergoline wins on nearly every axis, which is why it has become first-line. The one place bromocriptine retains an edge is pregnancy: it has decades more accumulated safety data in women who conceive on treatment, and some clinicians still prefer it for women actively trying to conceive for that reason alone. That is a decision for an endocrinologist who knows your case.

Buying Caberlin online

Cabergoline is prescription-only in the United States, United Kingdom, Australia and Canada. It is not a drug to self-prescribe, and the reason is not bureaucratic. Raised prolactin has multiple possible causes: a pituitary adenoma, hypothyroidism, chronic kidney disease, an antipsychotic or antiemetic you are taking, chest wall stimulation, or simply a blood draw done under stress or after a meal. The correct response to each of those is different, and only one of them is cabergoline. Suppressing a symptom without knowing its cause is how a pituitary tumour goes unmonitored.

You need, at minimum, a confirmed prolactin level (usually repeated, because a single elevated result is unreliable), thyroid function, and imaging if the level is significantly raised. Then a dose decision, then follow-up levels to guide titration, then an echocardiogram if treatment will be long term.

SafeRxPills stocks Caberlin 0.25mg at $21.00, manufactured through the Actiza Pharmaceutical Pvt. Ltd. supply chain from Surat, India, under WHO-GMP and ISO certification, Drug Licence 20B/GJ/SUR-111193. The 0.25mg strength is the correct starting strength, which is deliberate.

Browse the full women's health range for related products.

Medical disclaimer: this article is educational and is not a substitute for advice from a qualified healthcare professional. Cabergoline is a prescription medicine and raised prolactin requires proper investigation before treatment, because the cause determines the correct treatment. Speak to a doctor or endocrinologist before starting it, and do not stop or change the dose of any existing medication on the basis of this article.

References: DailyMed prescribing information, cabergoline tablets. FDA Orange Book, cabergoline approved products. PubMed PMID: 7935656, comparison of cabergoline and bromocriptine in hyperprolactinaemic amenorrhoea. PubMed PMID: 17202454, valvular heart disease and dopamine agonists in Parkinson's disease.